These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 32431227)

  • 1. COVID-19 and hypertension.
    Kulkarni S; Jenner BL; Wilkinson I
    J Renin Angiotensin Aldosterone Syst; 2020; 21(2):1470320320927851. PubMed ID: 32431227
    [No Abstract]   [Full Text] [Related]  

  • 2. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.
    Vaduganathan M; Vardeny O; Michel T; McMurray JJV; Pfeffer MA; Solomon SD
    N Engl J Med; 2020 Apr; 382(17):1653-1659. PubMed ID: 32227760
    [No Abstract]   [Full Text] [Related]  

  • 3. Coronavirus Disease 2019 (COVID-19): Do Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect?
    Sommerstein R; Kochen MM; Messerli FH; Gräni C
    J Am Heart Assoc; 2020 Apr; 9(7):e016509. PubMed ID: 32233753
    [No Abstract]   [Full Text] [Related]  

  • 4. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
    Patel AB; Verma A
    JAMA; 2020 May; 323(18):1769-1770. PubMed ID: 32208485
    [No Abstract]   [Full Text] [Related]  

  • 5. Drugs and the renin-angiotensin system in covid-19.
    Aronson JK; Ferner RE
    BMJ; 2020 Apr; 369():m1313. PubMed ID: 32241880
    [No Abstract]   [Full Text] [Related]  

  • 6. The interplay of hypertension, ACE-2 and SARS-CoV-2: Emerging data as the "Ariadne's thread" for the "labyrinth" of COVID-19.
    Tsioufis C; Dimitriadis K; Tousoulis D
    Hellenic J Cardiol; 2020; 61(1):31-33. PubMed ID: 32450334
    [No Abstract]   [Full Text] [Related]  

  • 7. Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.
    Furuhashi M; Moniwa N; Takizawa H; Ura N; Shimamoto K
    Hypertens Res; 2020 Aug; 43(8):837-840. PubMed ID: 32433641
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of ACEIs/ARBs in COVID-19: Friend or foe?
    Zhou Z; Qiu Y; Tao J
    Med Hypotheses; 2020 Sep; 142():109810. PubMed ID: 32413701
    [No Abstract]   [Full Text] [Related]  

  • 9. SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs.
    Ciulla MM
    Hypertens Res; 2020 Sep; 43(9):985-986. PubMed ID: 32523133
    [No Abstract]   [Full Text] [Related]  

  • 10. Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
    Huang Y; Xie C; Chen X; Hong Q; Huang H
    Pharmacol Res; 2020 Sep; 159():104959. PubMed ID: 32505834
    [No Abstract]   [Full Text] [Related]  

  • 11. COVID-19 and the cardiovascular system.
    Zheng YY; Ma YT; Zhang JY; Xie X
    Nat Rev Cardiol; 2020 May; 17(5):259-260. PubMed ID: 32139904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?
    Esler M; Esler D
    J Hypertens; 2020 May; 38(5):781-782. PubMed ID: 32195824
    [No Abstract]   [Full Text] [Related]  

  • 13. A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019).
    Talreja H; Tan J; Dawes M; Supershad S; Rabindranath K; Fisher J; Valappil S; van der Merwe V; Wong L; van der Merwe W; Paton J
    N Z Med J; 2020 Apr; 133(1512):85-87. PubMed ID: 32242182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Facts and reflections on COVID-19 and anti-hypertensives drugs.
    Marin GH
    Drug Discov Ther; 2020 May; 14(2):105-106. PubMed ID: 32213760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 and cardiovascular disease: What we know, what we think we know, and what we need to know.
    Dhawan R; Gundry RL; Brett-Major DM; Mahr C; Thiele GM; Lindsey ML; Anderson DR
    J Mol Cell Cardiol; 2020 Jul; 144():12-14. PubMed ID: 32339565
    [No Abstract]   [Full Text] [Related]  

  • 16. Central involvement of SARS-CoV-2 may aggravate ARDS and hypertension.
    Cure E; Cumhur Cure M; Vatansev H
    J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320972015. PubMed ID: 33169637
    [No Abstract]   [Full Text] [Related]  

  • 17. ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective.
    South AM; Brady TM; Flynn JT
    Hypertension; 2020 Jul; 76(1):16-22. PubMed ID: 32367746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular disease, heart failure and COVID-19.
    Faconti L; Chowienczyk PJ; Shah AM
    J Renin Angiotensin Aldosterone Syst; 2020; 21(2):1470320320926903. PubMed ID: 32434431
    [No Abstract]   [Full Text] [Related]  

  • 19. COVID-19 and the pulmonary vascular injury.
    Dai HL; Guang XF
    J Renin Angiotensin Aldosterone Syst; 2020; 21(4):1470320320972276. PubMed ID: 33176538
    [No Abstract]   [Full Text] [Related]  

  • 20. ACEI/ARB therapy in COVID-19: the double-edged sword of ACE2 and SARS-CoV-2 viral docking.
    Onweni CL; Zhang YS; Caulfield T; Hopkins CE; Fairweather L; Freeman WD
    Crit Care; 2020 Jul; 24(1):475. PubMed ID: 32736573
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.